Aging Brain Changes, Executive Dysfunction and Depression (FA)
|ClinicalTrials.gov Identifier: NCT00918684|
Recruitment Status : Completed
First Posted : June 11, 2009
Results First Posted : May 12, 2017
Last Update Posted : May 12, 2017
|Condition or disease||Intervention/treatment||Phase|
|Depression||Drug: Escitalopram||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||116 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Aging White Matter Changes, Executive Dysfunction and Depression|
|Actual Study Start Date :||December 2002|
|Actual Primary Completion Date :||May 2010|
|Actual Study Completion Date :||May 2010|
12-week open label with 2 week placebo period (14 weeks total)
10mg tab daily
Other Name: Lexapro
- Hamilton Depression Rating Scale. [ Time Frame: 14 weeks (12th week of treatment) ]A published and widely-used scale for rating depression severity, the Hamilton Depression Rating Scale 24 item total scores range from 0-76. Higher scores indicate greater severity of depression. Total scores are reported with no subscales.
- WHODAS-II Disability Scale [ Time Frame: 14 weeks (12th week of treatment) ]A disability rating scale published by the World Health Organization, the WHODAS II total scores can range from 0-100. Higher scores indicate greater severity of disability. Total scores are reported with no subscales.
- Stroop Color-Word Test [ Time Frame: 14 weeks (12th week of treatment) ]A published and widely used executive dysfunction test, the Stroop Color-Word total scores can range from 0-100. Higher scores indicate better memory functioning (no cognitive impairment). Total scores are reported with no subscales.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00918684
|Principal Investigator:||George S Alexopoulos, MD||Weill Medical College of Cornell University|